Merck Adds Biosimilar Capabilities, Insmed Gets Fresh Start In $130M Deal
A virtually broke biotech finds itself flush with cash while a major pharma's recently launched follow-on biologics play now enjoys an expanded pipeline and increased research and manufacturing capabilities - that's the outcome of a transaction labeled "a win/win for both parties" by Insmed CEO Geoffrey Allan
You may also be interested in...
The company's Japanese subsidiary Banyu Pharmaceutical has started domestic trials for its generic erythropoietin, poised to be Merck's first biosimilar launch.
With the acquisition, Merck gains a contract manufacturing organization with specific expertise in microbial-derived biologics.
Pfizer gains wide access to test-drive antibody-enhancing tools via new licensing deal.